Biotech Stock Report 10.03.09
Tuesday, 10 March, 2009
The pharmaceuticals and biotechnology sector was mostly flat recording a small 0.11% increase for the day.
Market heavyweight CSL (ASX:CSL) was stable, up 28c to $35.44.
Living Cell Technologies (ASX:LCT) recorded spectacular increase of 31%, to close at 10.5c but is still trading near its 52 week low of 8c.
Prana Biotechnology (ASX:PBT) and IDT Australia (ASX:IDT) were among the day's weaker performers in the pharmaceuticals and biotechnology sector, down 8% and 6% respectively with Bionomics Limited (ASX:BNO) not far behind, 5% down to 20c.
Chemgenex Pharmaceuticals (ASX:CXS) recorded a solid 6% rise to 34c, but is still well down on its 52 week high of $1.25. Novogen and Progen also moved up over 3%.
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
